PHASE I PK STUDY OF BMS-247550 IN ADVANCED MALIGNANCIES AND LIVER DYSFUNCTION

BMS-247550 在晚期恶性肿瘤和肝功能障碍中的 I 期 PK 研究

• 批准号: 7375518
• 负责人: GEORGE WILDING
• 金额: $ 0.37万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7375518
• 关键词: PHASE; PK; STUDY; BMS; 247550

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. (Clinical trial summary from the National Cancer Institute's PDQ database) Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. This is a Phase I trial to study the effectiveness of BMS-247550 in treating patients who have advanced solid tumors or lymphomas and liver dysfunction. Patients will receive a 3-hour infusion of BMS-247550 every 3 weeks. Treatment may continue for as long as benefit is shown. Patients will be evaluated periodically for 1 month.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心机构，不一定为研究者机构。（来自国家癌症研究所PDQ数据库的临床试验总结）化疗中使用的药物以不同的方式阻止肿瘤细胞分裂，使其停止生长或死亡。 这是一项I期试验，旨在研究BMS-247550治疗晚期实体瘤或淋巴瘤和肝功能障碍患者的有效性。 患者将每3周一次接受BMS-247550输注3小时。治疗可以持续，只要显示出益处。患者将接受为期1个月的定期评估。